Cited by 456Head and Neck Cancer StudiesCancer, Hypoxia, and MetabolismRadiation Therapy and Dosimetry

Hypoxic Modification of Radiotherapy in Squamous Cell Carcinoma of the Head and Neck - A Systematic Review and Meta-Analysis

Overgaard, Jens·2011·Radiotherapy and Oncology

Abstract

Background The importance of tumour hypoxia for the outcome of radiotherapy has been under investigation for decades. Numerous clinical trials modifying the hypoxic radioresistance in squamous cell carcinoma of the head and neck (HNSCC) have been conducted, but most have been inconclusive, partly due to a small number of patients in the individual trial. The present meta-analysis was, therefore, performed utilising the results from all clinical trials addressing the specific question of hypoxic modification in HNSCC undergoing curative intended primary radiotherapy alone.Methods A systematic review of published and unpublished data identified 4805 patients with HNSCC treated in 32 randomized clinical trials, applying, normobaric oxygen or carbogen breathing (5 trials); hyperbaric oxygen (HBO) (9 trials); hypoxic radiosensitizers (17 trials) and HBO and radiosensitizer (1 trial). The trials were analysed with regard to the following endpoints: loco-regional control (32 trials), disease specific survival (30 trials), overall survival (29 trials), distant metastases (12 trials) and complications to radiotherapy (23 trials).Results Overall hypoxic modification of radiotherapy in head and neck cancer did result in a significant improved therapeutic benefit. This was most dominantly observed when using the direct endpoint of loco-regional control with an odds ratio (OR) of 0.71, 95% cf.l. 0.63-0.80; p<0.001), but this was almost mirrored in the disease specific survival (OR: 0.73, 95% cf.l. 0.64-0.82; p<0.001), and to a lesser extent in the overall survival (OR: 0.87, 95% cf.l. 0.77-0.98; p=0.03). The risk of distant metastases was not significantly influenced although it appears to be less in the tumours treated with hypoxic modification (OR: 0.87, 95% cf.l. 0.69-1.09; p=0.22), whereas the radiation related late complications were not influenced by the overall use of hypoxic modifications (OR: 1.00, 95% cf.l. 0.82-1.23; p=0.96). The improvement in loco-regional control was found to be independent of the type of hypoxic modification. The trials have used different fractionation schedules, including large doses per fraction, which may result in relatively more hypoxia and greater benefit. However, analysis of HNSCC trials using conventional fractionation only, showed that the significant effect of hypoxic modification was maintained.Conclusion The meta-analysis thus demonstrates that there is level 1a evidence in favour of adding hypoxic modification to radiotherapy of squamous cell carcinomas of the head and neck.

Integrity signals

Registry

Crossref · 10.1016/j.radonc.2011.03.004

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Hyperbaric O2 (HBO) could have some activity in squamous cancers of the head and neck in radiotherapy.

    “Anti-hypoxia therapies have already been introduced in case of radiotherapy using hyperbaric O2 (HBO), which could have some activity in squamous cancers of the head and neck [91].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Overgaard, J.
Affiliations
Aarhus University Hospital (DK)
Corresponding author
Overgaard, Jens
Venue
Radiotherapy and Oncology
Publisher
Elsevier BV
Published
2011-07
Volume
100
Issue
1
Pages
22-32
ISSN
0167-8140 (ISSN-L)
OpenAlex
W2053662954
Cited by
456
References
115
Citations by year
2026: 13 · 2025: 16 · 2024: 20 · 2023: 25 · 2022: 25 · 2021: 39 · 2020: 32 · 2019: 30 · 2018: 20 · 2017: 38 · 2016: 44 · 2015: 42 · 2014: 26 · 2013: 37 · 2012: 29
FWCI
6.83
Type
journal article
Language
en
Open access
closed
Locations
  • Radiotherapy and Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • CIRRO – The Lundbeck Foundation Center for Interventional Research in Radiation Oncology
  • Danish Research Council
  • Danish Cancer Society
Topics
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Radiation Therapy and Dosimetry
Keywords
tumor hypoxia, head and neck squamous cell carcinoma, hypoxic radiosensitizer, hyperbaric oxygen therapy, normobaric oxygen, carbogen, locoregional control, disease-specific survival, overall survival, distant metastasis, primary radiotherapy, radioresistance (biology)
MeSH terms
Squamous Cell Carcinoma of Head and Neck, Hypoxia, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Humans, Neoplasm Metastasis, Radiotherapy, Radiotherapy Dosage

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review